Three-year clinical outcomes of resistance genotyping and expert advice: Extended follow-up of the Argenta trial

Andrea De Luca, Simona Di Giambenedetto, Antonella Cingolani, Alessandra Bacarelli, Adriana Ammassari, Roberto Cauda

Research output: Contribution to journalArticle

Abstract

Objective: To investigate the influence of genotypic resistance-guided HIV-treatment decisions on long-term clinical and virological outcomes in patients failing antiretroviral therapy by a prospective 30-month observation following a 6-month randomized study (Argenta trial). Methods: Patients (n=174) with virological failure on highly active antiretroviral therapy (HAART) were initially randomized (1:1) to receive empirical therapy or guidance by genotypic resistance results. After month 6, all patients with HIV RNA >1,000 copies/ml received genotypic resistance tests and expert advice. Predictors of virological and clinical outcomes were analysed by logistic regression and Cox's regression models. Results: There was a gradual increase in the proportion of patients with HIV RNA

Original languageEnglish
Pages (from-to)321-327
Number of pages7
JournalAntiviral Therapy
Volume11
Issue number3
Publication statusPublished - 2006

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Three-year clinical outcomes of resistance genotyping and expert advice: Extended follow-up of the Argenta trial'. Together they form a unique fingerprint.

  • Cite this

    De Luca, A., Di Giambenedetto, S., Cingolani, A., Bacarelli, A., Ammassari, A., & Cauda, R. (2006). Three-year clinical outcomes of resistance genotyping and expert advice: Extended follow-up of the Argenta trial. Antiviral Therapy, 11(3), 321-327.